By Research Area
Hot products 
-
Mouse Anti-CCNH Recombinant Antibody (CBFYC-1054) (CBMAB-C1111-FY)
-
Mouse Anti-ASTN1 Recombinant Antibody (H-9) (CBMAB-1154-CN)
-
Mouse Anti-CD63 Recombinant Antibody (CBXC-1200) (CBMAB-C1467-CQ)
-
Rat Anti-CD63 Recombinant Antibody (7G4.2E8) (CBMAB-C8725-LY)
-
Mouse Anti-CDK7 Recombinant Antibody (CBYY-C1783) (CBMAB-C3221-YY)
-
Mouse Anti-ACVR1C Recombinant Antibody (V2-179685) (CBMAB-A1041-YC)
-
Mouse Anti-CTNND1 Recombinant Antibody (CBFYC-2414) (CBMAB-C2487-FY)
-
Mouse Anti-CCDC25 Recombinant Antibody (CBLC132-LY) (CBMAB-C9786-LY)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CBC05) (CBMAB-CR005LY)
-
Mouse Anti-CASP8 Recombinant Antibody (CBYY-C0987) (CBMAB-C2424-YY)
-
Mouse Anti-AFDN Recombinant Antibody (V2-58751) (CBMAB-L0408-YJ)
-
Mouse Anti-EIF4G1 Recombinant Antibody (2A9) (CBMAB-A2544-LY)
-
Mouse Anti-AP4E1 Recombinant Antibody (32) (CBMAB-A2996-YC)
-
Rabbit Anti-AKT2 (Phosphorylated S474) Recombinant Antibody (V2-556130) (PTM-CBMAB-0605LY)
-
Mouse Anti-BRD3 Recombinant Antibody (CBYY-0801) (CBMAB-0804-YY)
-
Rabbit Anti-ENO2 Recombinant Antibody (BA0013) (CBMAB-0272CQ)
-
Mouse Anti-ARSA Recombinant Antibody (CBYC-A799) (CBMAB-A3679-YC)
-
Mouse Anti-APOH Recombinant Antibody (4D9A4) (CBMAB-A3249-YC)
-
Mouse Anti-CCN2 Recombinant Antibody (CBFYC-2383) (CBMAB-C2456-FY)
-
Mouse Anti-BIRC3 Recombinant Antibody (315304) (CBMAB-1214-CN)
Post-Translational Modification (PTM) Research
While the central dogma delineates the canonical pathway of genetic information flow, the functional maturation of the proteome extends significantly beyond initial protein synthesis. To achieve biological activity, nascent polypeptide chains frequently undergo a sophisticated suite of covalent modifications, collectively termed Post-Translational Modifications (PTMs). This process represents a fundamental mechanism for amplifying the functional repertoire of the proteome, far surpassing the complexity encoded by the genome itself. Consequently, a single genetic locus can ultimately yield a multiplicity of protein isoforms, each perhaps possessing a unique physiological role.
The scope of these modifications is extensive, playing a pivotal role in virtually all aspects of cellular regulation. PTMs encompass a diverse array of chemical alterations to proteins. These modifications range from the addition of small functional groups, including phosphate (phosphorylation), methyl (methylation), and acetyl groups (acetylation), to the conjugation of larger macromolecules, such as glycosylation and ubiquitination. Such changes can profoundly modulate a protein's physicochemical properties, thereby influencing its conformation, subcellular localization, catalytic activity, and participation in molecular interaction networks. Phosphorylation, for instance, is a ubiquitous regulatory switch. In contrast, the ligation of ubiquitin chains often earmarks a protein for proteasomal degradation, thus controlling its cellular half-life. It is increasingly clear that the precise and dynamic regulation of PTMs is indispensable for the fidelity of core processes like signal transduction, DNA repair, and the orchestration of gene expression.
Understanding PTMs is critical for unraveling complex diseases, including cancer and neurodegenerative disorders, where these pathways are often dysregulated. To facilitate investigations into these complex regulatory networks, Creative Biolabs provides a comprehensive portfolio of antibody reagents meticulously developed for PTM-centric research. These reagents are rigorously validated to ensure high specificity and performance across a spectrum of standard immunological applications, including Western Blot, ELISA, immunofluorescence, chromatin immunoprecipitation (ChIP), and flow cytometry. Our objective is to furnish the scientific community with robust tools that empower deeper exploration into the fundamental roles of post-translational modifications in health and disease.
Loading...
Compare
